Related Experiment Video

Updated: Jul 31, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Inhibition of angiogenesis as a strategy for tumor growth control

W F Herblin1, J L Gross

  • 1Du Pont Merck Pharmaceutical Company, Wilmington, DE.

Molecular and Chemical Neuropathology
|February 1, 1994
PubMed

Insights

Inhibiting angiogenesis, the formation of new blood vessels, can suppress tumor growth. Targeting basic fibroblast growth factor offers a potential strategy for anti-angiogenesis cancer therapy.

Area of Science:

  • Oncology
  • Vascular Biology
  • Biochemistry

Background:

  • Angiogenesis is crucial for normal processes like wound healing.
  • In adults, aberrant angiogenesis is linked to pathological conditions, notably solid tumor development.
  • Basic fibroblast growth factor (bFGF) is a key mediator of angiogenesis.

Purpose of the Study:

  • To review the role of angiogenesis in tumor development.
  • To explore the potential of inhibiting angiogenesis as an anti-cancer strategy.
  • To examine the antagonism of bFGF as a method for angiogenesis inhibition.

Main Methods:

  • Literature review of studies on angiogenesis and tumor growth.
  • Analysis of the role of basic fibroblast growth factor in angiogenesis.
  • Evaluation of evidence supporting angiogenesis inhibition for tumor suppression.

Main Results:

  • Angiogenesis is a critical factor in the growth and progression of solid tumors.
  • Inhibiting angiogenesis, particularly through bFGF antagonism, shows promise in suppressing tumor growth.
  • Evidence suggests a direct correlation between reduced angiogenesis and decreased tumor proliferation.

Conclusions:

  • Targeting angiogenesis represents a viable therapeutic strategy for cancer treatment.
  • Antagonizing basic fibroblast growth factor is a potential pathway to inhibit tumor-induced angiogenesis.
  • Further research into anti-angiogenesis therapies could lead to novel cancer treatments.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.